Research output per year
Research output per year
Fingerprint
Dive into the research topics where Robin van Geel is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Antibody-Drug Conjugates in Non-small Cell Lung Cancer
Zullo, L., Bortolot, M., Ogliari, F. R., Saw, S. P. L., van Geel, R., ter Heine, R., Sadowska, A., Remon, J. & Hendriks, L., Jul 2026, In: Drugs. 86, 7, p. 1045-1073 29 p.Research output: Contribution to journal › (Systematic) Review article › peer-review
Open Access -
Assessing the efficacy of a single-cycle measurement and adjustment strategy for direct oral anticoagulants in frail older patients: rationale and design of the DOAC-FRAIL randomized controlled trial
Magdelijns, F. J. H., de Jong, M. J., Winckers, K., Brys, A. D. H., Braeken, D. C. W., van Kuijk, S. M. J., Spronk, H. M. H., Bosman, H., Janssen, D. J. A., van Geel, R. M. J. M., Hellenbrand, D., ten Cate, H. & Henskens, Y., May 2026, In: Research and practice in thrombosis and haemostasis. 10, 4, 10 p., 106800.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Concordance of Lung Cancer, Melanoma, and Renal Cell Cancer Diagnosis Information Recorded in Health Care Databases in England: Analysis of Linkage Between Primary Care, Hospital Care, and Cancer Registry Data
Kruithof, P. D., Souverein, P. C., Driessen, J. H. M., Hendriks, L. E. L., Croes, S. & Van Geel, R. M. J. M., 14 Jan 2026, In: Pharmacoepidemiology and Drug Safety. 35, 1, 15 p., e70299.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Advancing leptomeningeal metastases treatment in EGFR-mutated non-small cell lung cancer: lessons from the BLOSSOM trial
Bortolot, M., Huijs, J. W. J., Brandsma, D., Compter, A., van Geel, R. M. J. M. & Hendriks, L. E. L., 24 Jan 2025, In: Translational Lung Cancer Research. 14, 1, p. 7-13 7 p.Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
Open Access -
De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Remon, J., Bortolot, M., Bironzo, P., Cortiula, F., Menis, J., Brandao, M., Naidoo, J., van Geel, R., Reguart, N., Arrieta, O., Mountzios, G., Hendriks, L. E. L. & Besse, B., 20 Mar 2025, In: Journal of Clinical Oncology. 43, 9, p. 1148-1156 11 p., 2402347.Research output: Contribution to journal › (Systematic) Review article › peer-review
Open AccessFile130 Downloads (Pure)
Activities
-
Geneesmiddelinteracties met DOAC’s, en de rol van Therapeutic Drug Monitoring
van Geel, R. (Speaker)
2026Activity: Talk or presentation / Performance / Speeches › Talk or presentation - at conference › Academic
-
Het meten van DOAC’s: mogelijkheden en valkuilen.
van Geel, R. (Speaker)
2025Activity: Talk or presentation / Performance / Speeches › Talk or presentation - at conference › Academic
-
Geplande studie 68Ga-FAPI-46 versus 18F-FDG as PET tracers in NSCLC en de rol van de apotheek bij de productie van 68Ga-FAPI-46 in het hotlab.
van Geel, R. (Speaker)
2025Activity: Talk or presentation / Performance / Speeches › Talk or presentation - at conference › Academic
-
Ontwikkelen van evidence-based dosisadvies om tyrosinekinaseremmers veilig te kunnen combineren met direct werkende anticoagulantia bij patiënten met longkanker.
van Geel, R. (Speaker)
2025Activity: Talk or presentation / Performance / Speeches › Performance, Talk or Presentation - not at conference › Academic
-
Special Interest Group radiofarmacie NVZA (External organisation)
van Geel, R. (Member)
2022 → …Activity: Membership (due to research expertise) › Membership of committee › Academic